Jane Hook

3.6k total citations · 1 hit paper
25 papers, 1.5k citations indexed

About

Jane Hook is a scholar working on Reproductive Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jane Hook has authored 25 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Reproductive Medicine, 9 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jane Hook's work include Ovarian cancer diagnosis and treatment (12 papers), Intraperitoneal and Appendiceal Malignancies (6 papers) and Sarcoma Diagnosis and Treatment (6 papers). Jane Hook is often cited by papers focused on Ovarian cancer diagnosis and treatment (12 papers), Intraperitoneal and Appendiceal Malignancies (6 papers) and Sarcoma Diagnosis and Treatment (6 papers). Jane Hook collaborates with scholars based in United Kingdom, Netherlands and Australia. Jane Hook's co-authors include Timothy Perren, M Mascarenhas, Selina Bannoo, Stephen Dobbs, Matthew Nankivell, Gordon C. Jayson, Jeremy Twigg, David Luesley, Jonathan Herod and Sean Kehoe and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Jane Hook

22 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

2015 945 citations Sean Kehoe, Jane Hook et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jane Hook United Kingdom	14	1.0k	706	486	417	292	25	1.5k
Michele Peiretti Italy	22	1.1k 1.1×	823 1.2×	1.0k 2.1×	389 0.9×	211 0.7×	51	1.9k
Dongyan Cao China	23	898 0.9×	336 0.5×	806 1.7×	338 0.8×	188 0.6×	129	1.7k
A Fanucchi Italy	24	833 0.8×	390 0.6×	631 1.3×	420 1.0×	181 0.6×	64	1.6k
Rafael S. Tomacruz United States	6	1.7k 1.7×	1.2k 1.7×	896 1.8×	280 0.7×	255 0.9×	6	2.0k
Jacob Korach Israel	24	886 0.9×	222 0.3×	565 1.2×	567 1.4×	144 0.5×	107	1.6k
Henric Malmström Sweden	14	1.2k 1.2×	721 1.0×	799 1.6×	478 1.1×	287 1.0×	30	1.8k
James J. Burke United States	17	674 0.7×	267 0.4×	984 2.0×	242 0.6×	214 0.7×	27	1.6k
Annika Auranen Finland	23	930 0.9×	385 0.5×	492 1.0×	316 0.8×	127 0.4×	72	1.6k
M. Lahousen Austria	22	1.2k 1.2×	665 0.9×	1.0k 2.1×	348 0.8×	298 1.0×	82	1.9k
Soon‐Beom Kang South Korea	24	616 0.6×	288 0.4×	821 1.7×	312 0.7×	152 0.5×	62	1.5k

Countries citing papers authored by Jane Hook

Since Specialization

Citations

This map shows the geographic impact of Jane Hook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Hook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Hook more than expected).

Fields of papers citing papers by Jane Hook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Hook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Hook. The network helps show where Jane Hook may publish in the future.

Co-authorship network of co-authors of Jane Hook

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Hook. A scholar is included among the top collaborators of Jane Hook based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Hook. Jane Hook is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ullah, Waqas, et al.. (2025). Discriminative Accuracy of CHA2DS2-VASc Score, and Development of Predictive Accuracy Model Using Machine Learning for Ischemic Stroke Risk in Cardiac Amyloidosis and Atrial Fibrillation. Cardiology Research. 16(5). 385–393.

Hook, Jane. (2024). Virtual Reality + Heart Rate Variability Biofeedback Pain Effects in Older Adults with Knee Osteoarthritis. Pain Management Nursing. 25(2). e171–e171. 1 indexed citations

Corrie, Pippa, Helen Marshall, Ruth Plummer, et al.. (2021). The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer. 21(1). 761–761. 18 indexed citations

Clamp, Andrew R., Elizabeth C James, Iain A. McNeish, et al.. (2020). 805O ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology. 31. S610–S610. 1 indexed citations

Blagden, Sarah P., Adrian Cook, Christopher Poole, et al.. (2020). Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. The Lancet Oncology. 21(7). 969–977. 17 indexed citations

Giannoudi, Marilena, Julie Lynch, Elaine Dunwoodie, et al.. (2020). MON-290 Ipilimumab Immune-Related ACTH Deficiency Is of Acute Onset and Severe. Journal of the Endocrine Society. 4(Supplement_1).

Danson, Sarah, et al.. (2019). Are we over-treating with checkpoint inhibitors?. British Journal of Cancer. 121(8). 629–630. 13 indexed citations

McNeish, Iain A., Andrew Dean, David Gallardo, et al.. (2017). ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis. Annals of Oncology. 28. v627–v627. 38 indexed citations

James, Elizabeth C, Jane Hook, SP Stenning, et al.. (2016). ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. 27. vi297–vi297.

10.

Kehoe, Sean, Jane Hook, Matthew Nankivell, et al.. (2015). Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. The Lancet. 386(9990). 249–257. 945 indexed citations breakdown →

11.

Smeland, Sigbjørn, Jeremy Whelan, Stefan Bielack, et al.. (2015). Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1.. Journal of Clinical Oncology. 33(15_suppl). 10512–10512. 2 indexed citations

12.

Khalique, Saira, Jane Hook, & Jonathan A. Ledermann. (2014). Maintenance therapy in ovarian cancer. Current Opinion in Oncology. 26(5). 521–528. 22 indexed citations

13.

Hook, Jane, Sally Stenning, James D. Brenton, et al.. (2014). ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer.. Journal of Clinical Oncology. 32(15_suppl). TPS5611–TPS5611. 3 indexed citations

14.

Bielack, Stefan, Sigbjørn Smeland, Jeremy Whelan, et al.. (2013). MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization.. Journal of Clinical Oncology. 31(18_suppl). LBA10504–LBA10504. 11 indexed citations

15.

McTiernan, Anne, Rachel C. Jinks, Matthew R. Sydes, et al.. (2011). Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup. European Journal of Cancer. 48(5). 703–712. 40 indexed citations

16.

Raja, Fharat, Jane Hook, & Jonathan A. Ledermann. (2011). Biomarkers in the development of anti-angiogenic therapies for ovarian cancer. Cancer Treatment Reviews. 38(6). 662–672. 16 indexed citations

17.

Whelan, Jeremy, Rachel C. Jinks, Anne McTiernan, et al.. (2011). Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Annals of Oncology. 23(6). 1607–1616. 156 indexed citations

18.

Sharma, Rohini, Jane Hook, Munish Kumar, & Hani Gabra. (2008). Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. European Journal of Cancer. 44(2). 251–256. 71 indexed citations

19.

Linch, Mark, et al.. (2008). Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer. Gynecologic Oncology. 109(1). 27–32. 18 indexed citations

20.

Fisher, Rosemary A., Philip Savage, Jane Hook, et al.. (2007). The impact of molecular genetic diagnosis on the management of women with hCG-producing malignancies. Gynecologic Oncology. 107(3). 413–419. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact